SOURCE: ImmuneRegen BioSciences, Inc.

December 01, 2008 06:30 ET

ImmuneRegen® Appoints Wound Healing and Tissue Regeneration Expert Spencer A. Brown, Ph.D. to Advisory Board

Company Gains Further Scientific and Biotech Business Expertise to Accelerate Development of, and the Opportunity for Clinical Trials for, New Wound Care Drug

SCOTTSDALE, AZ--(Marketwire - December 1, 2008) - ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), announced today that it appointed Spencer A. Brown, Ph.D., to its advisory board. Dr. Brown, who has more than 20 years experience as a clinical researcher and biotech company entrepreneur and advisor, is director of research of the plastic surgery department at the University of Texas Southwestern Medical Center (UTSW). He specializes in wound care, tissue regeneration and reconstructive surgery research.

"We are delighted Dr. Brown is joining our advisory board. He not only brings his extensive wound healing research that includes preclinical and clinical studies in stem cells, dermatology, reconstructive surgery and wound healing mechanisms, but also an understanding of the needs of biotech companies. His strategic counsel will be invaluable to our long-term growth and success," said Michael K. Wilhelm, ImmuneRegen president and CEO.

ImmuneRegen's drug candidate, Homspera®, is an adult stem cell active compound that has been shown to regenerate and strengthen the immune system and enhance wound healing. Dr. Brown and his research team at UTSW will perform additional research necessary to support ImmuneRegen's IND (Investigational New Drug) filing in an effort to obtain U.S. Food and Drug Administration clearance to initiate human wound healing studies. UTSW also will conduct studies to confirm Homspera's efficacy for additional skin applications.

"I am looking forward to working with ImmuneRegen's scientists and senior management to advance the promise Homspera has demonstrated in enhancing treatment and healing of wounds," Dr. Brown said. "I welcome the opportunity to work with a company that shows such promise."

Before joining Dallas-based UTSW as the director of research for the department of plastic surgery in 2000, Dr. Brown was professor faculty member at Duke University Medical Center, Durham, N.C. Previously, Dr. Brown was research instructor and research assistant professor at Baylor College of Medicine in Houston.

He is a member of the National Institutes of Health's Special Emphasis Board Study Section I K08 and Special Emphasis Board Study Section II, and UTSW's Institutional Board for Responsible Care for Human Subjects and Institutional Animal Care and Use Committee (IACUC). He has served on numerous society committee and reviewer for several journals.

Dr. Brown received his Bachelor of Arts degree from Gettysburg College and Ph.D. degree from the University of Pennsylvania, with a thesis on cholesterol metabolism. He completed a postdoctoral fellowship at the Section of Atherosclerosis and Lipid Metabolism at the Baylor College of Medicine. He has authored and co-authored more than 80 peer-reviewed articles and presented more than 60 abstracts at national meetings, including the Plastic Surgery Research Council, Wound Healing Society and American Society for Laser Medicine and Surgery.

About ImmuneRegen BioSciences, Inc.

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that, in study results, has been shown that it may have effects on the regeneration and strengthening of the immune system and on enhancing wound healing. To advance its mission, the Scottsdale, Arizona-based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems, Inc. For more information, please visit

Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the likelihood that FDA approval is obtained to initiate human wound healing studies, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended September 30, 2008 as filed on November 13, 2008, and on Form 10-KSB for the year ended December 31, 2007 as filed on March 31, 2008 and as amended on Form 10-KSB/A, Amendment No. 1 filed on September 25, 2008 with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.

Contact Information